{"id":"concomitant-cisplatin","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Anemia"},{"rate":"5-30%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Kidney damage"},{"rate":"5-10%","effect":"Hearing loss"},{"rate":"5-10%","effect":"Tinnitus"},{"rate":"5-10%","effect":"Neurotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which trigger DNA repair mechanisms and ultimately lead to cell death. This process is particularly effective in cancer cells, which have a high rate of cell division.","oneSentence":"Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:20.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Testicular cancer"},{"name":"Lung cancer"},{"name":"Bladder cancer"},{"name":"Stomach cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07008833","phase":"NA","title":"Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-06","conditions":"Muscle Invasive Bladder Cancer","enrollment":336},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT03040999","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-05","conditions":"Head and Neck Neoplasms","enrollment":804},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT07343531","phase":"NA","title":"A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-07-01","conditions":"Cervical Carcinoma Stage III, Cervical Carcinoma Stage IIB, Cervical Carcinoma Stage II","enrollment":30},{"nctId":"NCT07340489","phase":"PHASE2","title":"Serplulimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-03","conditions":"Cervical Cancer","enrollment":216},{"nctId":"NCT04367311","phase":"PHASE2","title":"Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nasser Hanna","startDate":"2020-05-22","conditions":"Lung Cancer, NSCLC","enrollment":100},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT06593639","phase":"NA","title":"Effect of Prehabilitation on Head and Neck Cancer Patients","status":"RECRUITING","sponsor":"Laura Deborah Locati","startDate":"2024-09-09","conditions":"Head and Neck Cancer","enrollment":60},{"nctId":"NCT02918955","phase":"PHASE3","title":"Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-12-16","conditions":"Head and Neck Neoplasms","enrollment":65},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT04459715","phase":"PHASE3","title":"A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2020-08-07","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":730},{"nctId":"NCT06560697","phase":"NA","title":"Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma","status":"RECRUITING","sponsor":"National Institute of Cancerología","startDate":"2024-05-15","conditions":"Uterine Cervical Neoplasm","enrollment":84},{"nctId":"NCT07177443","phase":"PHASE3","title":"Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-25","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":456},{"nctId":"NCT05570422","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01","status":"NOT_YET_RECRUITING","sponsor":"Kortuc, Inc.","startDate":"2025-12-01","conditions":"Cervical Cancer","enrollment":70},{"nctId":"NCT00210171","phase":"PHASE2","title":"Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Institut Bergonié","startDate":"2004-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":""},{"nctId":"NCT04378023","phase":"","title":"Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.","status":"RECRUITING","sponsor":"Hospital Vall d'Hebron","startDate":"2020-04-24","conditions":"Unresectable Cholangiocarcinoma","enrollment":34},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT07064902","phase":"PHASE2","title":"Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":48},{"nctId":"NCT05388773","phase":"PHASE2","title":"Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer","status":"RECRUITING","sponsor":"Heath Skinner","startDate":"2022-07-20","conditions":"Oropharynx Cancer","enrollment":150},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT07015892","phase":"PHASE3","title":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2025-09-01","conditions":"Small Cell Lung Carcinoma","enrollment":300},{"nctId":"NCT03612791","phase":"PHASE2","title":"Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-08-13","conditions":"Locally Advanced Cervical Cancer","enrollment":189},{"nctId":"NCT04821765","phase":"PHASE2","title":"Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10-01","conditions":"Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease","enrollment":35},{"nctId":"NCT06156514","phase":"PHASE3","title":"Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer","status":"RECRUITING","sponsor":"National Institute of Cancerología","startDate":"2019-11-06","conditions":"Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy","enrollment":140},{"nctId":"NCT03255252","phase":"PHASE2","title":"Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy","status":"TERMINATED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-07-15","conditions":"Cervical Cancer","enrollment":29},{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03576417","phase":"PHASE3","title":"A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2018-10-10","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":680},{"nctId":"NCT02998385","phase":"PHASE3","title":"Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-01-20","conditions":"HNSCC","enrollment":342},{"nctId":"NCT06924619","phase":"PHASE2","title":"Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-10-30","conditions":"Locally Advanced Thymoma","enrollment":178},{"nctId":"NCT03527264","phase":"PHASE2","title":"BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2018-11-08","conditions":"Cervical Cancer","enrollment":4},{"nctId":"NCT04251065","phase":"PHASE2","title":"Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-09-03","conditions":"Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma","enrollment":8},{"nctId":"NCT06786780","phase":"PHASE2","title":"Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids","status":"ENROLLING_BY_INVITATION","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-01-01","conditions":"Cervical Cancer Treated with Pelvic Radiotherapy, Cervical Cancers","enrollment":50},{"nctId":"NCT06882473","phase":"NA","title":"A Clinical Study of Pelvic Concurrent Chemoradiotherapy Combined with CT-guided Intracavitary Brachytherapy with Adaptive Simultaneous Dose Escalation for Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-15","conditions":"Locally Advanced Cervical Cancer","enrollment":20},{"nctId":"NCT06880289","phase":"PHASE2","title":"Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2020-09-16","conditions":"Squamous Cell Tumors of the Head and Neck","enrollment":91},{"nctId":"NCT06869239","phase":"","title":"Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02-25","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":65},{"nctId":"NCT01648023","phase":"PHASE2","title":"Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin","status":"COMPLETED","sponsor":"Robert C. Martin","startDate":"2012-07","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":49},{"nctId":"NCT03058289","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","status":"COMPLETED","sponsor":"Intensity Therapeutics, Inc.","startDate":"2017-02-09","conditions":"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":111},{"nctId":"NCT03721757","phase":"PHASE2","title":"CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer","status":"COMPLETED","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2019-05-10","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":21},{"nctId":"NCT06714708","phase":"PHASE2","title":"Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2024-11-20","conditions":"NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy","enrollment":86},{"nctId":"NCT05944809","phase":"PHASE2","title":"The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients","status":"COMPLETED","sponsor":"JIANYANG WANG","startDate":"2023-07-20","conditions":"Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy","enrollment":32},{"nctId":"NCT04275713","phase":"PHASE2","title":"Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2020-05-22","conditions":"Cervical Cancer","enrollment":41},{"nctId":"NCT06087614","phase":"PHASE2","title":"Dose Escalation Using Hypoxia-adjusted Radiotherapy","status":"RECRUITING","sponsor":"Rajiv Gandhi Cancer Institute & Research Center, India","startDate":"2024-04-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT06752135","phase":"","title":"Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience","status":"TERMINATED","sponsor":"Azienda Policlinico Umberto I","startDate":"2024-04-10","conditions":"Cervical Carcinoma","enrollment":97},{"nctId":"NCT05966194","phase":"PHASE2","title":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"EpicentRx, Inc.","startDate":"2024-04-02","conditions":"Oral Mucositis","enrollment":216},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74},{"nctId":"NCT05182112","phase":"PHASE1","title":"Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-20","conditions":"Pancreatic Cancer","enrollment":1},{"nctId":"NCT00868491","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT05487391","phase":"PHASE3","title":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-12-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":632},{"nctId":"NCT05203913","phase":"PHASE2","title":"Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-05-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":32},{"nctId":"NCT06137378","phase":"PHASE2","title":"European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-04-17","conditions":"Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":140},{"nctId":"NCT02129699","phase":"PHASE3","title":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-01-06","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":595},{"nctId":"NCT05913427","phase":"PHASE2","title":"Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)","status":"RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2022-06-08","conditions":"Adrenocortical Carcinoma","enrollment":80},{"nctId":"NCT04116047","phase":"PHASE3","title":"CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-07","conditions":"Oropharyngeal Cancer","enrollment":785},{"nctId":"NCT06462378","phase":"PHASE2","title":"Proton Therapy for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-05-20","conditions":"Cervical Cancer, Proton Therapy, Radiotherapy Side Effect","enrollment":55},{"nctId":"NCT06426056","phase":"PHASE2","title":"Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-06","conditions":"Cervical Cancer","enrollment":64},{"nctId":"NCT06421610","phase":"PHASE1","title":"OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-15","conditions":"Malignant Pleural Effusion, Pleural Neoplasms, Quality of Life","enrollment":20},{"nctId":"NCT02778191","phase":"","title":"Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2016-02","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":413},{"nctId":"NCT06401447","phase":"NA","title":"TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT04212052","phase":"PHASE2","title":"Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":104},{"nctId":"NCT02556762","phase":"PHASE3","title":"Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer","status":"UNKNOWN","sponsor":"Chuangzhen Chen","startDate":"2015-08","conditions":"Esophageal Cancer","enrollment":202},{"nctId":"NCT01693718","phase":"PHASE2","title":"A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2003-03","conditions":"Head and Neck","enrollment":44},{"nctId":"NCT03532737","phase":"PHASE2","title":"Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer","status":"UNKNOWN","sponsor":"Kuwait Cancer Control Center","startDate":"2018-10-07","conditions":"Locally Advanced Head and Neck Cancer","enrollment":50},{"nctId":"NCT00030771","phase":"PHASE3","title":"Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2001-04-04","conditions":"Lung Cancer","enrollment":232},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT05092412","phase":"PHASE2","title":"Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC","status":"UNKNOWN","sponsor":"You Lu","startDate":"2022-03-02","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab","enrollment":30},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT05173272","phase":"PHASE3","title":"Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2023-07-24","conditions":"Cervical Cancer","enrollment":286},{"nctId":"NCT06170697","phase":"PHASE2","title":"Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT04070976","phase":"NA","title":"Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer","status":"UNKNOWN","sponsor":"National Institute of Cancerología","startDate":"2019-07-01","conditions":"Cervical Cancer","enrollment":82},{"nctId":"NCT05406856","phase":"NA","title":"PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-05-02","conditions":"Uterine Cervical Neoplasms, Locally Advanced Cervical Carcinoma","enrollment":30},{"nctId":"NCT05217212","phase":"","title":"Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?","status":"UNKNOWN","sponsor":"Luzerner Kantonsspital","startDate":"2020-01-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT05128630","phase":"PHASE2","title":"Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2021-10-28","conditions":"NSCLC, Stage III","enrollment":45},{"nctId":"NCT06048926","phase":"NA","title":"Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03534713","phase":"PHASE3","title":"Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2020-07-17","conditions":"Cervical Cancer TNM Staging Regional Lymph Nodes (N)","enrollment":310},{"nctId":"NCT00648648","phase":"PHASE1","title":"A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-25","conditions":"Solid Tumors","enrollment":206},{"nctId":"NCT05661188","phase":"PHASE2","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","status":"RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2023-02-14","conditions":"Squamous Cell Carcinoma of the Anal Canal","enrollment":45},{"nctId":"NCT05511623","phase":"PHASE2","title":"Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-09-01","conditions":"Cervical Cancer","enrollment":112},{"nctId":"NCT03865277","phase":"PHASE2","title":"Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging","status":"NOT_YET_RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-07-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":276},{"nctId":"NCT04953962","phase":"PHASE2","title":"Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"CanBas Co. Ltd.","startDate":"2021-12-18","conditions":"Pancreatic Cancer Stage IV","enrollment":36},{"nctId":"NCT05076942","phase":"PHASE2","title":"Groningen International Study on Sentinel Nodes in Vulvar Cancer-III","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2021-01-01","conditions":"Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases","enrollment":157},{"nctId":"NCT01633541","phase":"PHASE2","title":"Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2012-03","conditions":"Laryngeal Cancer","enrollment":55},{"nctId":"NCT05946577","phase":"","title":"Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07","conditions":"Head Cancer, Neck Cancer","enrollment":140},{"nctId":"NCT00047008","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-07","conditions":"Head and Neck Cancer","enrollment":743},{"nctId":"NCT00003298","phase":"PHASE2","title":"Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-06-01","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT03214003","phase":"NA","title":"Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC","status":"COMPLETED","sponsor":"Anhui Shi, MD","startDate":"2017-06-30","conditions":"Small Cell Lung Cancer Limited Stage, Radiotherapy","enrollment":235},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT05879796","phase":"","title":"Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-05-16","conditions":"Cervical Cancer","enrollment":30},{"nctId":"NCT04019548","phase":"PHASE3","title":"Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2019-12-16","conditions":"Oropharyngeal Cancer","enrollment":110},{"nctId":"NCT05504642","phase":"PHASE2","title":"Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients","status":"WITHDRAWN","sponsor":"Universitätsklinikum Köln","startDate":"2023-11-01","conditions":"Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"concomitant cisplatin","genericName":"concomitant cisplatin","companyName":"Groupe Oncologie Radiotherapie Tete et Cou","companyId":"groupe-oncologie-radiotherapie-tete-et-cou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells. Used for Ovarian cancer, Testicular cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}